Q2 2026 Investor Update

Strong performance.
Focused execution.

Chairman's Executive Comments

Everest enters the second half of 2026 from a position of strength. The quarter affirmed the economics of our platform, with continued progress in revenue, profitability and patient census. More importantly, it gives us the financial capacity and leadership stability to focus on the work that creates durable long-term value.

Our next phase is about disciplined execution: improving census, retention and referrals within the clinics we already operate; opening Ellsworth responsibly; and advancing the next regional opportunity without getting ahead of our people or capital. With Heather Camara and Paul Makowski leading the organization and greater depth in finance, I believe we have the right team and a clear agenda for the balance of the year.

Key results and trends

The Q2 investor view

Five confirmed indicators summarize the quarter, with the underlying quarterly history available on demand.

Q2 revenue$2.379M

+41.8% versus Q2 2025

Operating income$678K

+138.7% versus Q2 2025

Operating margin28.5%

+11.6 pts versus Q2 2025

Net income$573K

+95.3% versus Q2 2025

Quarter-end census801

+40 patients since Q1

Investor perspective

The financial foundation is strong. The next value-creation opportunity is converting that strength into consistent patient growth, clinic-level execution and disciplined expansion.

Verified against the ERC Consolidated 2025 and 2026 Trend Reports generated August 3, 2026. All financial figures are actuals through June 30, 2026; census uses verified quarter-end clinic reports.

Investor takeawayQ2 revenue increased 41.8% from Q2 2025 and 5.5% from Q1 2026.

Revenue does not decline at the quarterly checkpoints shown. If a future decline is not explained by the financial categories available in the source reports, management detail will be requested before commentary is published.

Financial results are quarterly totals derived from the ERC Consolidated Trend Reports. Census uses the clinic reports nearest each quarter end, beginning with Q1 2025.

Growth and outlook

Build on the platform already in place.

The strategy prioritizes execution in existing clinics, a responsible Ellsworth opening and selective regional expansion.

Grow existing clinics

Increase census, retention and referral development.

Open our fifth clinic

Complete development, staffing, licensure and opening readiness for Ellsworth.

Expand with discipline

Advance selected opportunities in Maine and Massachusetts.

Leadership and staffing

Greater operating and financial depth

Four leaders are strengthening accountability, continuity and disciplined growth.

Permanent appointment

Heather Camara

Chief Executive Officer

Responsible for enterprise leadership, organizational execution and company performance.

Expanded operating leadership

Paul Makowski

Chief Operating Officer

Focused on clinic operations and consistent execution. His former HR leadership role has already been backfilled.

Expanded development leadership

Mike Cabral

Infrastructure & New Clinic Development

Mike has stepped up to lead every new de novo clinic from lease execution through licensure. His ownership of Ellsworth—Everest's fifth clinic—reflects the accountability and disciplined execution supporting our next phase of growth.

Internal promotion

Ashley Farrell

Accounting Manager

Leads monthly close, financial reporting and internal-control improvements, with an Accounting Assistant backfilling portions of her prior duties.